Schizophrenia is classified among the world’s top ten enduring disabilities. Hearing voices are a profound and distressing symptom, which have proven difficult to successfully treat. We plan to use the latest brain imaging techniques and genetic testing to develop the most comprehensive understanding of hearing for voices to date. These data are vital to the development of novel tailored treatment for patients who hear voices.
Antipsychotic Medication In First-episode Psychosis: An RCT To Assess The Risk-benefit Ratio
Funder
National Health and Medical Research Council
Funding Amount
$1,141,117.00
Summary
There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.
Dopamine Neuron Ontogeny: Convergent Neurobiological Pathway For Risk Factors Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$337,214.00
Summary
Schizophrenia is associated with changes in dopamine (a signalling molecule in the brain). These changes are present prior to psychosis, suggesting they begin early in development. Our aims are to manipulate key factors in the development of brain dopamine systems to clarify their role in psychosis and schizophrenia. This work has the potential to identify early brain changes that lead to schizophrenia, which in turn may generate better diagnoses and outcomes for people with this disorder.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
Epistatic Genetic Effects On Neuroanatomical Subtypes Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$410,141.00
Summary
Schizophrenia represents a number of clinically distinct syndromes, with a complex mode of inheritance. The delineation of biologically valid subtypes of schizophrenia is necessary to advance our understanding of the genetic basis of these syndromes. This project uses pattern classification techniques to determine subtypes of schizophrenia on the basis of structural brain abnormality across multiple regions, and will examine genetic interactions and differential gene expression associated with t ....Schizophrenia represents a number of clinically distinct syndromes, with a complex mode of inheritance. The delineation of biologically valid subtypes of schizophrenia is necessary to advance our understanding of the genetic basis of these syndromes. This project uses pattern classification techniques to determine subtypes of schizophrenia on the basis of structural brain abnormality across multiple regions, and will examine genetic interactions and differential gene expression associated with these biologically-derived subtypes.Read moreRead less
Application Of Intelligent Conducting Polymers For Treating Schizophrenia And Allied Disorders Focusing On Neuronal Outgrowth, Myelination And Synaptogenesis
Funder
National Health and Medical Research Council
Funding Amount
$698,314.00
Summary
This project involves cross-disciplinary collaboration between researchers at the forefront of materials engineering, nanotechnology, neural pathology, human stem cell biology and mental health disciplines. We will use a nanodevice to apply electrical stimuli and growth factors to improve brain function in schizophrenia and allied disorders.
A Dimensional Approach To Mapping The Risk Mechanisms Of Mental Illness
Funder
National Health and Medical Research Council
Funding Amount
$1,677,975.00
Summary
There is ongoing debate about whether current definitions of mental disorders are accurate. We will use statistical techniques to identify the core dimensions of liability for mental illness, and map how genes and brain organization drive differences between people along each dimension.
Acceptance And Commitment Therapy For Medication-resistant Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$558,200.00
Summary
In spite of advances in medication, approximately one third of people with schizophrenia continue to experience distressing symptoms such as hearing voices and paranoia. Psychological 'talking treatments' are effective in helping people to cope with and be less distressed by these experiences. This study will be the first trial of a new psychological treatment, called Acceptance and Commitment Therapy, which may be more effective, briefer and more easily provided than existing approaches.